. Author manuscript; available in PMC: 2024 Mar 22.

Published in final edited form as: Int J Radiat Biol. 2023 Mar 22;99(7):1055–1065. doi: 10.1080/09553002.2023.2188933

Table 4.

Combined drugs that improve survival after lethal irradiation alone (RI) or combined radiation with wound or burn trauma (CI).

2 drugs	Species	Rad. dose	Admin. route	Admin. doses	Improvement		References
2 drugs	Species	Rad. dose	Admin. route	Admin. doses	RI	CI	References
Neulasta + Alxn4100TPO	B6D2F1 female mice	9.5 Gy ⁶⁰Co	SC; SC	1mg/kg sc + 1d, +8d, +15d; 1 mg/kg sc, +1d	Yes for survival	Yes for survival	Kiang et al. Radiat Res 2017; 188, 476–490.
Neulasta + Ghrelin	B6D2F1 female mice	9.5 Gy ⁶⁰Co	SC; SC	1mg/kg sc + 1d, +8d, +15d; 113 μg/kg; once +1d, +2d, +3dμ	Yes for survival	No for survival	Kiang et al. Front Pharmacol 2021; 2021:628018
Neulasta + Ciprofloxacin	B6D2F1 female mice	9.5 Gy Co-60	SC; PO	1mg/kg sc + 1d, +8d, +15d; 90 mg/kg, po once, +2 hr, +1d–+21dμ	Yes for survival	No for survival	Kiang et al. in preparation
Neulasta + L-Citrulline	B6D2F1 female mice	9.5 Gy ⁶⁰Co	SC; PO	1mg/kg sc +1d, +8d, +15d; 1 g/kg; po once +1d-21d	Yes for survival	almost for survival	Wang et al. Radiat Res 2021; 196, 113–127
S-TDCM + Gentamicin	C3H/HeN-J female mice	8Gy ⁶⁰Co	IP	200 mg/kg, immediately after irradiation	No for survival	Yes for survival	Ledny and Elliott, Health Phys 2010; 98(2), 145–152

Rad.: radiation; Admin.: administration; SC: subcutaneous; PO: per os (i.e., oral feed); IP: intrapreural; RI: radiation injury; CI: combined radiation injury.